Burden of vaccine-preventable diseases among at-risk adult populations in the US
Life-course immunization holds significant benefit for population health by reducing the burden of vaccine-preventable diseases (VPD) through vaccinating individuals at different stages and circumstances in life. The study aimed to determine the epidemiologic, clinical, economic, and societal burden...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-11-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2022.2054602 |
| _version_ | 1797673182064279552 |
|---|---|
| author | Irina Kolobova Mawuli Kwame Nyaku Anna Karakusevic Daisy Bridge Iain Fotheringham Megan O'Brien |
| author_facet | Irina Kolobova Mawuli Kwame Nyaku Anna Karakusevic Daisy Bridge Iain Fotheringham Megan O'Brien |
| author_sort | Irina Kolobova |
| collection | DOAJ |
| description | Life-course immunization holds significant benefit for population health by reducing the burden of vaccine-preventable diseases (VPD) through vaccinating individuals at different stages and circumstances in life. The study aimed to determine the epidemiologic, clinical, economic, and societal burden of VPDs among at-risk adult subpopulations in the United States. A systematic literature review was conducted for articles published between January 2010 and June 2020, which identified 72 publications. There was heterogeneity in available epidemiology data, with the prevalence of VPDs ranging from 1.1% to 68.7%. Where the disease burden was described, outcomes were typically worse among high-risk subpopulations than in the general population. Several VPDs, including herpes zoster, meningococcal, and pneumococcal infections were associated with increased costs. This review suggests that subpopulations may not frequently interact with the healthcare system, or their risk factors may not be recognized by healthcare providers, and therefore individuals may not be appropriately targeted for vaccination. |
| first_indexed | 2024-03-11T21:41:20Z |
| format | Article |
| id | doaj.art-0aba6e39ca7e471ca80813cb2754308a |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T21:41:20Z |
| publishDate | 2022-11-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-0aba6e39ca7e471ca80813cb2754308a2023-09-26T13:19:06ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2022-11-0118510.1080/21645515.2022.20546022054602Burden of vaccine-preventable diseases among at-risk adult populations in the USIrina Kolobova0Mawuli Kwame Nyaku1Anna Karakusevic2Daisy Bridge3Iain Fotheringham4Megan O'Brien5Merck & Co., IncMerck & Co., IncAdelphi Values PROVEAdelphi Values PROVEAdelphi Values PROVEMerck & Co., IncLife-course immunization holds significant benefit for population health by reducing the burden of vaccine-preventable diseases (VPD) through vaccinating individuals at different stages and circumstances in life. The study aimed to determine the epidemiologic, clinical, economic, and societal burden of VPDs among at-risk adult subpopulations in the United States. A systematic literature review was conducted for articles published between January 2010 and June 2020, which identified 72 publications. There was heterogeneity in available epidemiology data, with the prevalence of VPDs ranging from 1.1% to 68.7%. Where the disease burden was described, outcomes were typically worse among high-risk subpopulations than in the general population. Several VPDs, including herpes zoster, meningococcal, and pneumococcal infections were associated with increased costs. This review suggests that subpopulations may not frequently interact with the healthcare system, or their risk factors may not be recognized by healthcare providers, and therefore individuals may not be appropriately targeted for vaccination.http://dx.doi.org/10.1080/21645515.2022.2054602vaccine-preventable diseaseslife-course immunizationat-risk populationdisease burdenpublic healthpopulation health |
| spellingShingle | Irina Kolobova Mawuli Kwame Nyaku Anna Karakusevic Daisy Bridge Iain Fotheringham Megan O'Brien Burden of vaccine-preventable diseases among at-risk adult populations in the US Human Vaccines & Immunotherapeutics vaccine-preventable diseases life-course immunization at-risk population disease burden public health population health |
| title | Burden of vaccine-preventable diseases among at-risk adult populations in the US |
| title_full | Burden of vaccine-preventable diseases among at-risk adult populations in the US |
| title_fullStr | Burden of vaccine-preventable diseases among at-risk adult populations in the US |
| title_full_unstemmed | Burden of vaccine-preventable diseases among at-risk adult populations in the US |
| title_short | Burden of vaccine-preventable diseases among at-risk adult populations in the US |
| title_sort | burden of vaccine preventable diseases among at risk adult populations in the us |
| topic | vaccine-preventable diseases life-course immunization at-risk population disease burden public health population health |
| url | http://dx.doi.org/10.1080/21645515.2022.2054602 |
| work_keys_str_mv | AT irinakolobova burdenofvaccinepreventablediseasesamongatriskadultpopulationsintheus AT mawulikwamenyaku burdenofvaccinepreventablediseasesamongatriskadultpopulationsintheus AT annakarakusevic burdenofvaccinepreventablediseasesamongatriskadultpopulationsintheus AT daisybridge burdenofvaccinepreventablediseasesamongatriskadultpopulationsintheus AT iainfotheringham burdenofvaccinepreventablediseasesamongatriskadultpopulationsintheus AT meganobrien burdenofvaccinepreventablediseasesamongatriskadultpopulationsintheus |